John P. Moore

55.7k total citations · 13 hit papers
384 papers, 37.5k citations indexed

About

John P. Moore is a scholar working on Virology, Immunology and Infectious Diseases. According to data from OpenAlex, John P. Moore has authored 384 papers receiving a total of 37.5k indexed citations (citations by other indexed papers that have themselves been cited), including 314 papers in Virology, 153 papers in Immunology and 149 papers in Infectious Diseases. Recurrent topics in John P. Moore's work include HIV Research and Treatment (314 papers), Immune Cell Function and Interaction (121 papers) and HIV/AIDS drug development and treatment (116 papers). John P. Moore is often cited by papers focused on HIV Research and Treatment (314 papers), Immune Cell Function and Interaction (121 papers) and HIV/AIDS drug development and treatment (116 papers). John P. Moore collaborates with scholars based in United States, Netherlands and United Kingdom. John P. Moore's co-authors include Quentin J. Sattentau, Per Johan Klasse, Dennis R. Burton, Rogier W. Sanders, Joseph Sodroski, Alexandra Trkola, David D. Ho, James Μ. Binley, Ian A. Wilson and Tatjana Dragic and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

John P. Moore

379 papers receiving 36.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficient Neutralization of Primary Isolates of HIV-1 by a Recombinant Human Monoclonal Antibody

1994 938 citations Dennis R. Burton, John P. Moore et al. Science profile →
Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1

1996 925 citations John P. Moore et al. Journal of Virology profile →
CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5

1996 922 citations James Μ. Binley, William C. Olson et al. profile →
Crystal Structure of a Soluble Cleaved HIV-1 Envelope Trimer

2013 640 citations Jean‐Philippe Julien, Albert Cupo et al. Science profile →
AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor

1998 634 citations John P. Moore et al. profile →
Broadly Neutralizing Antibodies Targeted to the Membrane-Proximal External Region of Human Immunodeficiency Virus Type 1 Glycoprotein gp41

2001 632 citations James Μ. Binley, John P. Moore et al. Journal of Virology profile →
A Next-Generation Cleaved, Soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, Expresses Multiple Epitopes for Broadly Neutralizing but Not Non-Neutralizing Antibodies

2013 629 citations Rogier W. Sanders, Albert Cupo et al. PLoS Pathogens profile →
HIV vaccine design and the neutralizing antibody problem

2004 610 citations Dennis R. Burton, John P. Moore et al. profile →
Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding

1993 543 citations John P. Moore, David D. Ho et al. Journal of Virology profile →
Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding.

1991 531 citations Quentin J. Sattentau, John P. Moore profile →
Antibody Protects Macaques against Vaginal Challenge with a Pathogenic R5 Simian/Human Immunodeficiency Virus at Serum Levels Giving Complete Neutralization In Vitro

2001 530 citations John P. Moore, Dennis R. Burton et al. Journal of Virology profile →
Cryo-EM Structure of a Fully Glycosylated Soluble Cleaved HIV-1 Envelope Trimer

2013 527 citations Dmitry Lyumkis, Jean‐Philippe Julien et al. Science profile →
Dissociation of gp120 from HIV-1 Virions Induced by Soluble CD4

1990 517 citations John P. Moore, Quentin J. Sattentau et al. Science profile →

Peers

Countries citing papers authored by John P. Moore

Since Specialization

Citations

This map shows the geographic impact of John P. Moore's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John P. Moore with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John P. Moore more than expected).

Fields of papers citing papers by John P. Moore

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John P. Moore. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John P. Moore. The network helps show where John P. Moore may publish in the future.

Co-authorship network of co-authors of John P. Moore

This figure shows the co-authorship network connecting the top 25 collaborators of John P. Moore. A scholar is included among the top collaborators of John P. Moore based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John P. Moore. John P. Moore is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The RV144 Trial Might Still Yield Useful Information 2025 ·Current HIV Research ·John P. Moore	0
2	Glycan heterogeneity as a cause of the persistent fraction in HIV-1 neutralization 2023 ·PLoS Pathogens ·Rajesh P. Ringe, Philippe Colin, Gabriel Ozorowski, Joel D. Allen, Anila Yasmeen, Gemma E. Seabright, Jeong Hyun Lee, Aleksandar Antanasijevic, Kimmo Rantalainen, Thomas J. Ketas, John P. Moore, Andrew B. Ward, Max Crispin, Per Johan Klasse	5
3	Reappraising the Value of HIV-1 Vaccine Correlates of Protection Analyses 2022 ·Journal of Virology ·Per Johan Klasse, John P. Moore	12
4	T cell response in immunosuppressed redo-liver transplant recipients after COVID-19 infection and after first dose of vaccine against SARS-CoV-2 2021 ·White Rose Research Online (University of Leeds, The University of Sheffield, University of York) ·(unknown), (unknown), (unknown), (unknown), John P. Moore, (unknown), (unknown), (unknown), Emma Page, (unknown), Sinisa Savic	1
5	Immunogenicity of clinically relevant SARS-CoV-2 vaccines in nonhuman primates and humans 2021 ·Science Advances ·Per Johan Klasse, Douglas F. Nixon, John P. Moore	1
6	Antibody responses induced by SHIV infection are more focused than those induced by soluble native HIV-1 envelope trimers in non-human primates 2021 ·PLoS Pathogens ·Jelle van Schooten, Marlies M. van Haaren, Hui Li, Laura E. McCoy, Colin Havenar‐Daughton, Christopher A. Cottrell, Judith A. Burger, Patricia van der Woude, Leanne C. Helgers, Ilhan Tomris, Celia C. LaBranche, David C. Montefiori, Andrew B. Ward, Dennis R. Burton, John P. Moore, Rogier W. Sanders, Shane Crotty, George M. Shaw, Marit J. van Gils	12
7	High-resolution mapping of the neutralizing and binding specificities of polyclonal sera post-HIV Env trimer vaccination 2021 ·eLife ·Adam S. Dingens, (unknown), Keara D. Malone, Sarah K. Hilton, Thomas J. Ketas, Christopher A. Cottrell, Julie Overbaugh, John P. Moore, (unknown), Andrew B. Ward, Jesse D. Bloom	14
8	COVID-19 Vaccines: “Warp Speed” Needs Mind Melds, Not Warped Minds 2020 ·Journal of Virology ·John P. Moore, Per Johan Klasse	66
9	Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization 2020 ·eLife ·(unknown), John P. Moore	52
10	Optimizing the production and affinity purification of HIV-1 envelope glycoprotein SOSIP trimers from transiently transfected CHO cells 2019 ·PLoS ONE ·Albert Cupo, (unknown), (unknown), Anila Yasmeen, Per Johan Klasse, John P. Moore	15
11	Cryo-EM Structure of a Fully Glycosylated Soluble Cleaved HIV-1 Envelope Trimer breakdown → 2013 ·Science ·Dmitry Lyumkis, Jean‐Philippe Julien, Natalia de Val, Albert Cupo, Clinton S. Potter, (unknown), Dennis R. Burton, Rogier W. Sanders, John P. Moore, Bridget Carragher, Ian A. Wilson, Andrew B. Ward	527
12	Crystal Structure of a Soluble Cleaved HIV-1 Envelope Trimer breakdown → 2013 ·Science ·Jean‐Philippe Julien, Albert Cupo, Devin Sok, Robyn L. Stanfield, Dmitry Lyumkis, Marc C. Deller, (unknown), Dennis R. Burton, Rogier W. Sanders, John P. Moore, Andrew B. Ward, Ian A. Wilson	640
13	Partial Enzymatic Deglycosylation Preserves the Structure of Cleaved Recombinant HIV-1 Envelope Glycoprotein Trimers 2012 ·Journal of Biological Chemistry ·Rafael S. Depetris, Jean‐Philippe Julien, Reza Khayat, Jeong Hyun Lee, Robert Pejchal, Umesh Katpally, (unknown), (unknown), (unknown), (unknown), Albert Cupo, Andre J. Marozsan, William C. Olson, Andrew B. Ward, Ian A. Wilson, Rogier W. Sanders, John P. Moore	40
14	V3 determinants of HIV-1 escape from the CCR5 inhibitors Maraviroc and Vicriviroc (vol 427, pg 158, 2012) 2012 ·Virology ·Reem Berro, Per Johan Klasse, Martin R. Jakobsen, Paul R. Gorry, John P. Moore, Rogier W. Sanders	3
15	Targeting HIV-1 Envelope Glycoprotein Trimers to B Cells by Using APRIL Improves Antibody Responses 2011 ·Journal of Virology ·Mark Melchers, Ilja Bontjer, Tommy Tong, Nancy P. Y. Chung, Per Johan Klasse, Dirk Eggink, David C. Montefiori, (unknown), Andrea Cerutti, William C. Olson, Ben Berkhout, James Μ. Binley, John P. Moore, Rogier W. Sanders	39
16	Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41 2009 ·Proceedings of the National Academy of Sciences ·Cleo Anastassopoulou, Thomas J. Ketas, Per Johan Klasse, John P. Moore	84
17	Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency 2009 ·Proceedings of the National Academy of Sciences ·Paolo Ingallinella, Elisabetta Bianchi, (unknown), Yingjie Wang, Renee Hrin, Maria Veneziano, Fabio Bonelli, Thomas J. Ketas, John P. Moore, Michael D. Miller, Antonello Pessi	184
18	Identification of Human Immunodeficiency Virus Type 1 Glycoprotein gp120/gp41 Interacting Sites by the Idiotypic Mimicry of Two Monoclonal Antibodies 1993 ·AIDS Research and Human Retroviruses ·Lucia Lopalco, Renato Longhi, (unknown), Anita De Rossi, Micaela Pelagi, (unknown), John P. Moore, Thomas F. Schulz, Alberto Beretta, Antonio G. Siccardi	23
19	Adaptation of Two Primary Human Immunodeficiency Virus Type 1 Isolates to Growth in Transformed T Cell Lines Correlates with Alterations in the Responses of Their Envelope Glycoproteins to Soluble CD4 1993 ·AIDS Research and Human Retroviruses ·John P. Moore, Linda C. Burkly, Ruth I. Connor, (unknown), Richard Tizard, David D. Ho, (unknown)	75
20	Enhancement of Soluble CD4-Mediated HIV Neutralization and gp120 Binding by CD4 Autoantibodies and Monoclonal Antibodies 1990 ·AIDS Research and Human Retroviruses ·John P. Moore, Quentin J. Sattentau, Paul R. Clapham	18

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact